(Bloomberg) -- Munich Re and Marsh & McLennan Cos., the largest insurancebroker by market value, introduced a product to insure U.S.pharmaceutical companies against regulatory actions that couldcause them to suspend manufacturing.

The product would cover as much as $10 million in non- damagebusiness-interruption costs tied to violations of federalmanufacturing standards, Munich Re said Wednesday in a statement.The Munich-based company is the world’s biggest reinsurer.

“The question is always, ‘Where do you find kind of the nextblockbuster?’” Claudia Hasse, head of special enterprise risks forMunich Re, said in a phone interview. “We saw that this is really ahuge danger for pharmaceutical companies.”

Continue Reading for Free

Register and gain access to:

  • Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
  • Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Commercial Lines
E&S/Specialty
Reinsurance
Corporate Risk
Loss Control